Shots:

• The additional insight from the P-IIb CaLIPSO study showed that SNF472 slowed the progression of CAC across key subgroups of patients on hemodialysis participating in the study. The presentation highlights the PK/PD and exposure-response analyses
• Sanifit also presents the design of its ongoing P-III CALCIPHYX study evaluating the efficacy and safety of SNF472 for the treatment of patients with calciphylaxis (calcific uremic arteriolopathy- or CUA). Additional data demonstrated that SNF472 strongly inhibits valvular calcification in an in vitro model of porcine aortic valve
• SNF472 is an inhibitor of vascular calcification currently in P-III study- acts by targeting the deposition of solid calcium (hydroxyapatite- HAP) in the CV system. The company is showcasing new data on SNF472 in four presentations including one oral session and three ePoster sessions at virtual ASN Kidney Week 2020

 ­ Ref: Sanifit | Image: European Biotechnology